➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Harvard Business School

Last Updated: June 22, 2021

DrugPatentWatch Database Preview

XULTOPHY 100/3.6 Drug Profile

Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for XULTOPHY 100/3.6

Identify potential brand extensions & biosimilar entrants

Novo Nordisk A/SPhase 4
The Cleveland ClinicPhase 4
Novo Nordisk A/SN/A

See all XULTOPHY 100/3.6 clinical trials

Recent Litigation for XULTOPHY 100/3.6

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc.2017-03-03
Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc.2017-03-02

See all XULTOPHY 100/3.6 litigation

Patent Text Search: US Patents for XULTOPHY 100/3.6

These patents were identified by searching patent claims

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.